# Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer

> **NCT00006229** · PHASE2,PHASE3 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 774 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** carboplatin
- **DRUG:** paclitaxel
- **DRUG:** rebimastat

## Key facts

- **NCT ID:** NCT00006229
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-04-04
- **Primary completion:** 2003-12-10
- **Final completion:** 2009-02-10
- **Target enrollment:** 774 (ACTUAL)
- **Last updated:** 2020-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006229, "Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00006229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*